|
|
|||||||||||||||||||||||||||||||||||||||
|
Intra-Cellular Therapies Inc (ITCI) Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery, clinical development and commercialization of small molecule drugs that address medical needs mainly in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. Co.'s product candidate, CAPLYTA™ (lumateperone) has been approved for the treatment of schizophrenia in adults. Co. is developing ITI-1284, an oral disintegrating tablet for sublingual administration for the treatment of behavioral disturbances in patients with dementia and dementia-related psychosis and for the treatment of certain depressive disorders in the elderly.
|
|
|||||||||||||||||||||||||||||||||||||||
Free ITCI Email Alerts:
Intra-Cellular Therapies Inc (ITCI) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.